-
1
-
-
0034693754
-
Signaling network of the Btk family kinases
-
Qiu, Y. and Kung, H. J. (2000) Signaling network of the Btk family kinases Oncogene 19, 5651-5661
-
(2000)
Oncogene
, vol.19
, pp. 5651-5661
-
-
Qiu, Y.1
Kung, H.J.2
-
2
-
-
36349003312
-
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells
-
Jiang, X., Borgesi, R. A., McKnight, N. C., Kaur, R., Carpenter, C. L., and Balk, S. P. (2007) Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells J. Biol. Chem. 282, 32689-32698
-
(2007)
J. Biol. Chem.
, vol.282
, pp. 32689-32698
-
-
Jiang, X.1
Borgesi, R.A.2
McKnight, N.C.3
Kaur, R.4
Carpenter, C.L.5
Balk, S.P.6
-
3
-
-
18444404925
-
Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy
-
Citri, A., Alroy, I., Lavi, S., Rubin, C., Xu, W., Grammatikakis, N., Patterson, C., Neckers, L., Fry, D. W., and Yarden, Y. (2002) Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy EMBO J. 21, 2407-2417
-
(2002)
EMBO J.
, vol.21
, pp. 2407-2417
-
-
Citri, A.1
Alroy, I.2
Lavi, S.3
Rubin, C.4
Xu, W.5
Grammatikakis, N.6
Patterson, C.7
Neckers, L.8
Fry, D.W.9
Yarden, Y.10
-
4
-
-
33748071774
-
Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse
-
Dai, B., Kim, O., Xie, Y., Guo, Z., Xu, K., Wang, B., Kong, X., Melamed, J., Chen, H., Bieberich, C. J., Borowsky, A. D., Kung, H. J., Wei, G., Ostrowski, M. C., Brodie, A., and Qiu, Y. (2006) Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse Cancer Res. 66, 8058-8064
-
(2006)
Cancer Res.
, vol.66
, pp. 8058-8064
-
-
Dai, B.1
Kim, O.2
Xie, Y.3
Guo, Z.4
Xu, K.5
Wang, B.6
Kong, X.7
Melamed, J.8
Chen, H.9
Bieberich, C.J.10
Borowsky, A.D.11
Kung, H.J.12
Wei, G.13
Ostrowski, M.C.14
Brodie, A.15
Qiu, Y.16
-
5
-
-
77954370361
-
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells
-
Dai, B., Chen, H., Guo, S., Yang, X., Linn, D. E., Sun, F., Li, W., Guo, Z., Xu, K., Kim, O., Kong, X., Melamed, J., Qiu, S., Chen, H., and Qiu, Y. (2010) Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells Cancer Res. 70, 5587-5596
-
(2010)
Cancer Res.
, vol.70
, pp. 5587-5596
-
-
Dai, B.1
Chen, H.2
Guo, S.3
Yang, X.4
Linn, D.E.5
Sun, F.6
Li, W.7
Guo, Z.8
Xu, K.9
Kim, O.10
Kong, X.11
Melamed, J.12
Qiu, S.13
Chen, H.14
Qiu, Y.15
-
6
-
-
53149132043
-
The development of HKI-272 and related compounds for the treatment of cancer
-
Wissner, A. and Mansour, T. S. (2008) The development of HKI-272 and related compounds for the treatment of cancer Arch. Pharm. 341, 465-477
-
(2008)
Arch. Pharm.
, vol.341
, pp. 465-477
-
-
Wissner, A.1
Mansour, T.S.2
-
7
-
-
55249109749
-
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
-
Hur, W., Velentza, A., Kim, S., Flatauer, L., Jiang, X., Valente, D., Mason, D. E., Suzuki, M., Larson, B., Zhang, J., Zagorska, A., Didonato, M., Nagle, A., Warmuth, M., Balk, S. P., Peters, E. C., and Gray, N. S. (2008) Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase Bioorg. Med.Chem. Lett. 18, 5916-5919
-
(2008)
Bioorg. Med.Chem. Lett.
, vol.18
, pp. 5916-5919
-
-
Hur, W.1
Velentza, A.2
Kim, S.3
Flatauer, L.4
Jiang, X.5
Valente, D.6
Mason, D.E.7
Suzuki, M.8
Larson, B.9
Zhang, J.10
Zagorska, A.11
Didonato, M.12
Nagle, A.13
Warmuth, M.14
Balk, S.P.15
Peters, E.C.16
Gray, N.S.17
-
8
-
-
19744365702
-
A small molecule-kinase interaction map for clinical kinase inhibitors
-
Fabian, M. A., Biggs, W. H., III, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 23, 329-336
-
(2005)
Nat. Biotechnol.
, vol.23
, pp. 329-336
-
-
Fabian, M.A.1
Iii, H.B.W.2
Treiber, D.K.3
Atteridge, C.E.4
Azimioara, M.D.5
Benedetti, M.G.6
Carter, T.A.7
Ciceri, P.8
Edeen, P.T.9
Floyd, M.10
Ford, J.M.11
Galvin, M.12
Gerlach, J.L.13
Grotzfeld, R.M.14
Herrgard, S.15
Insko, D.E.16
Insko, M.A.17
Lai, A.G.18
Lelias, J.M.19
Mehta, S.A.20
Milanov, Z.V.21
Velasco, A.M.22
Wodicka, L.M.23
Patel, H.K.24
Zarrinkar, P.P.25
Lockhart, D.J.26
more..
-
9
-
-
38049018155
-
A quantitative analysis of kinase inhibitor selectivity
-
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., Faraoni, R., Floyd, M., Hunt, J. P., Lockhart, D. J., Milanov, Z. V., Morrison, M. J., Pallares, G., Patel, H. K., Pritchard, S., Wodicka, L. M., and Zarrinkar, P. P. (2008) A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26, 127-132
-
(2008)
Nat. Biotechnol.
, vol.26
, pp. 127-132
-
-
Karaman, M.W.1
Herrgard, S.2
Treiber, D.K.3
Gallant, P.4
Atteridge, C.E.5
Campbell, B.T.6
Chan, K.W.7
Ciceri, P.8
Davis, M.I.9
Edeen, P.T.10
Faraoni, R.11
Floyd, M.12
Hunt, J.P.13
Lockhart, D.J.14
Milanov, Z.V.15
Morrison, M.J.16
Pallares, G.17
Patel, H.K.18
Pritchard, S.19
Wodicka, L.M.20
Zarrinkar, P.P.21
more..
-
10
-
-
80755125575
-
Comprehensive analysis of kinase inhibitor selectivity
-
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29, 1046-1051
-
(2011)
Nat. Biotechnol.
, vol.29
, pp. 1046-1051
-
-
Davis, M.I.1
Hunt, J.P.2
Herrgard, S.3
Ciceri, P.4
Wodicka, L.M.5
Pallares, G.6
Hocker, M.7
Treiber, D.K.8
Zarrinkar, P.P.9
-
11
-
-
77957903550
-
Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)- 9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1 H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer
-
Liu, Q., Chang, J. W., Wang, J., Kang, S. A., Thoreen, C. C., Markhard, A., Hur, W., Zhang, J., Sim, T., Sabatini, D. M., and Gray, N. S. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9- (quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1 H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer J. Med. Chem. 53, 7146-7155
-
(2010)
J. Med. Chem.
, vol.53
, pp. 7146-7155
-
-
Liu, Q.1
Chang, J.W.2
Wang, J.3
Kang, S.A.4
Thoreen, C.C.5
Markhard, A.6
Hur, W.7
Zhang, J.8
Sim, T.9
Sabatini, D.M.10
Gray, N.S.11
-
12
-
-
72949092456
-
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
-
Zhou, W., Ercan, D., Chen, L., Yun, C. H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K. K., Eck, M. J., Gray, N. S., and Janne, P. A. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462, 1070-1074
-
(2009)
Nature
, vol.462
, pp. 1070-1074
-
-
Zhou, W.1
Ercan, D.2
Chen, L.3
Yun, C.H.4
Li, D.5
Capelletti, M.6
Cortot, A.B.7
Chirieac, L.8
Iacob, R.E.9
Padera, R.10
Engen, J.R.11
Wong, K.K.12
Eck, M.J.13
Gray, N.S.14
Janne, P.A.15
-
13
-
-
33644784776
-
An efficient rapid system for profiling the cellular activities of molecular libraries
-
Melnick, J. S., Janes, J., Kim, S., Chang, J. Y., Sipes, D. G., Gunderson, D., Jarnes, L., Matzen, J. T., Garcia, M. E., Hood, T. L., Beigi, R., Xia, G., Harig, R. A., Asatryan, H., Yan, S. F., Zhou, Y., Gu, X. J., Saadat, A., Zhou, V., King, F. J., Shaw, C. M., Su, A. I., Downs, R., Gray, N. S., Schultz, P. G., Warmuth, M., and Caldwell, J. S. (2006) An efficient rapid system for profiling the cellular activities of molecular libraries Proc. Natl. Acad. Sci. U.S.A. 103, 3153-3158
-
(2006)
Proc. Natl. Acad. Sci. U.S.A.
, vol.103
, pp. 3153-3158
-
-
Melnick, J.S.1
Janes, J.2
Kim, S.3
Chang, J.Y.4
Sipes, D.G.5
Gunderson, D.6
Jarnes, L.7
Matzen, J.T.8
Garcia, M.E.9
Hood, T.L.10
Beigi, R.11
Xia, G.12
Harig, R.A.13
Asatryan, H.14
Yan, S.F.15
Zhou, Y.16
Gu, X.J.17
Saadat, A.18
Zhou, V.19
King, F.J.20
Shaw, C.M.21
Su, A.I.22
Downs, R.23
Gray, N.S.24
Schultz, P.G.25
Warmuth, M.26
Caldwell, J.S.27
more..
-
14
-
-
33845360035
-
Ba/F3 cells and their use in kinase drug discovery
-
Warmuth, M., Kim, S., Gu, X. J., Xia, G., and Adrian, F. (2007) Ba/F3 cells and their use in kinase drug discovery Curr. Opin. Oncol. 19, 55-60
-
(2007)
Curr. Opin. Oncol.
, vol.19
, pp. 55-60
-
-
Warmuth, M.1
Kim, S.2
Gu, X.J.3
Xia, G.4
Adrian, F.5
-
15
-
-
77955625479
-
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
-
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., and Buggy, J. J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U.S.A. 107, 13075-13080
-
(2010)
Proc. Natl. Acad. Sci. U.S.A.
, vol.107
, pp. 13075-13080
-
-
Honigberg, L.A.1
Smith, A.M.2
Sirisawad, M.3
Verner, E.4
Loury, D.5
Chang, B.6
Li, S.7
Pan, Z.8
Thamm, D.H.9
Miller, R.A.10
Buggy, J.J.11
-
16
-
-
84871806385
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
-
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E., and Fowler, N. H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J. Clin. Oncol. 31, 88-94
-
(2013)
J. Clin. Oncol.
, vol.31
, pp. 88-94
-
-
Advani, R.H.1
Buggy, J.J.2
Sharman, J.P.3
Smith, S.M.4
Boyd, T.E.5
Grant, B.6
Kolibaba, K.S.7
Furman, R.R.8
Rodriguez, S.9
Chang, B.Y.10
Sukbuntherng, J.11
Izumi, R.12
Hamdy, A.13
Hedrick, E.14
Fowler, N.H.15
|